ALBO News and Press, Albireo Pharma Inc. From 05/21/21

– Bylvay has the potential to become first approved drug to treat all forms of PFIC – – CHMP opinion is based on the PEDFIC Phase 3 studies – – PEDFIC 1 met the bile acid (P=0.003) and pruritus (P=0.004) primary endpoints, with a diarrh...

Shares of Albireo Pharma have fallen ~30% from their post-secondary intraday highs as concerns about market potential and competition have muted any advance. The company’s lead asset, odevixibat, has a July 20th, 2021 PDUFA date for the treatment of PFIC, a bile acid indication...

- PEDFIC 1 and PEDFIC 2 Phase 3 data presentations on long-term safety, tolerability, and improved outcomes for patients with PFIC - - Data showing long-term treatment benefits of Bylvay™ (odevixibat ) , including improvements in total bilirubin, grow...

Mirum has two assets targeting rare liver diseases. Lead asset has a PDUFA in September. Current lows make MIRM interesting. For further details see: Mirum: Rare Disease Play With Upcoming Catalysts

The following slide deck was published by Albireo Pharma, Inc. in conjunction with their 2021 Q1 earnings call. For further details see: Albireo Pharma, Inc. 2021 Q1 - Results - Earnings Call Presentation

Albireo Pharma, Inc. (ALBO) Q1 2021 Earnings Conference Call May 06, 2021, 10:00 AM ET Company Participants Paul Bavier - GC Ron Cooper - President, CEO Simon Harford - CFO Pamela Stephenson - CCO Pat Horn - CMO Conference Call Participants Eun Yang - Jeffries Ritu Baral - Cowen and Company L...

Image source: The Motley Fool. Albireo Pharma, Inc. (NASDAQ: ALBO) Q1 2021 Earnings Call May 7, 2021 , 8:00 p.m. ET Operator Continue reading For further details see: Albireo Pharma, Inc. (ALBO) Q1 2021 Earnings Call Transcript

– Bylvay TM (odevixibat) commercial readiness on track for anticipated H2 21 launch in U.S. and EU– – Completed global commercial agreements for two key top ten markets – – ASSERT & BOLD Phase 3 studies enrolling and...

BOSTON, April 29, 2021 (GLOBE NEWSWIRE) -- Albireo Pharma, Inc. (Nasdaq: ALBO), a clinical-stage orphan pediatric liver disease company developing novel bile acid modulators, today announced that management will host a conference call and live audio webcast at 10:00 a.m. ET on May...

Albireo developed Odevixibat- a product as a pipeline - as a life saving therapy for multiple ultra rare pediatric liver disease indications. The market potential is in the billions and well reachable with the announced positive Phase 3 results and PDUFA date set on 21 July. Launc...